Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05637398
PHASE1/PHASE2

Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

Sponsor: I.M. Sechenov First Moscow State Medical University

View on ClinicalTrials.gov

Summary

Heart failure with preserved left ventricular ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Systemic low-grade inflammation is acknowledged to be a fundamental pathophysiological mechanism of HFpEF. Interventions targeting inflammatory pathway is understudied in HFpEF. Colchicine is a safe and well tolerated anti-inflammatory drug, which interferes with several steps in the inflammatory process. The drug has been extensively studied in different cardiovascular pathologies except HFpEF. We assume that colchicine decreases inflammation and reduces sST2 levels in HFpEF.

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2022-12-15

Completion Date

2025-11-01

Last Updated

2025-04-10

Healthy Volunteers

No

Interventions

DRUG

Colchicine

The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator

Locations (2)

A Shchendrygina

Moscow, Russia

Anastasia Shchendrygina

Moscow, Russia